TRCT
CAI

Tower Research Capital (TRC)’s Caris Life Sciences CAI Stock Holding History

Tower Research Capital (TRC)’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77K Sell
99
-41
-29% -$896 ﹤0.01% 4604
2025
Q4 		$3.78K Buy
140
+117
+509% +$3.29K ﹤0.01% 4315
2025
Q3 		$696 Sell
23
-2,085
-99% -$66.5K ﹤0.01% 4960
2025
Q2 		$56.3K Buy
+2,108
New +$56.8K ﹤0.01% 2871

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tower Research Capital (TRC)'s CAI Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Caris Life Sciences (CAI) stake by 29% in Q1 2026, selling an estimated $896 and leaving 99 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #4604.

Tower Research Capital (TRC) first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $56.3K in Q2 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Tower Research Capital (TRC) held 99 shares of Caris Life Sciences worth $1.77K as of Q1 2026.
  • Tower Research Capital (TRC) sold 41 Caris Life Sciences shares in Q1 2026, an estimated $896.
  • Caris Life Sciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4604 holding.
  • Tower Research Capital (TRC) first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Tower Research Capital (TRC)'s Caris Life Sciences position peaked at $56.3K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.